WORCESTER, Mass., Jan. 13, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is scheduled to present at the OneMedForum 2010 Conference being held at the Sir Francis Drake Hotel in San Francisco. Chairman, President and CEO Anna Gluskin will present a corporate overview today, Wednesday, January 13, 2010 at 12:00 pm Pacific Time (3:00 pm Eastern Time) and meet one-on-one with investors during the conference.
OneMedForum provides an opportunity for the most promising emerging healthcare and life science companies to present to and interact with a diverse group of global investors and partners. The forum is held at the Sir Francis Drake Hotel in San Francisco, during the Healthcare community's largest gathering of the year -- the J.P. Morgan Healthcare Conference.
About the OneMedForum 2010 Conference and OneMedPlace
Held annually in San Francisco, the OneMedForum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising -- and typically least recognized -- companies in the world. The conference's unique format of sector-oriented panel discussions, company presentations and investor meetings is designed to connect CEOs with appropriate institutional, venture and private investors.
OneMedPlace (OMP), the organizer of the OneMedForum, is a virtual community for those involved in bringing innovation to the market. It is one place to find the latest innovations in health and medicine and a portal to access the best information available for strategic and financial investors. Anchored by a database of over 7,000 companies, OMP provides an integrated set of research and multi-media communications tools which facilitate communications among those building the companies shaping the future of health and medicine.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.